

Douglas B Johnson, Msci

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5454152/douglas-b-johnson-msci-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

244
papers

17,111
citations

62
h-index

128
g-index

265
ext. papers

23,426
ext. citations

10.3
avg, IF

6.94
L-index

#	Paper	IF	Citations
244	Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. <i>Cell</i> , 2016 , 165, 35-44	56.2	1552
243	Fulminant Myocarditis with Combination Immune Checkpoint Blockade. <i>New England Journal of Medicine</i> , 2016 , 375, 1749-1755	59.2	1100
242	Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2018 , 4, 1721-1728	13.4	893
241	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020 , 395, 1907-1918	40	1880
240	Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. <i>New England Journal of Medicine</i> , 2017 , 376, 2211-2222	59.2	739
239	Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. <i>Cancer Discovery</i> , 2014 , 4, 80-93	24.4	700
238	Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. <i>JAMA Oncology</i> , 2016 , 2, 234-40	13.4	408
237	Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. <i>Lancet, The</i> , 2018 , 391, 933	40	407
236	Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. <i>Lancet Oncology, The</i> , 2018 , 19, 1579-1589	21.7	395
235	Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. <i>Cell</i> , 2015 , 162, 1271-85	56.2	377
234	Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. <i>Cancer Immunology Research</i> , 2016 , 4, 959-967	12.5	318
233	Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors 2019 , 7, 306		300
232	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2027-2039	5.1	293
231	Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. <i>Lancet Oncology, The</i> , 2018 , 19, 310-322	21.7	284
230	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. <i>Nature Communications</i> , 2016 , 7, 10582	17.4	248
229	Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. <i>Cancer Cell</i> , 2015 , 27, 240-56	24.3	226
228	Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2019 , 5, 1195-1204	13.4	224

227	sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. <i>Nature</i> , 2016 , 532, 250-4	50.4	205
226	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. <i>European Journal of Cancer</i> , 2015 , 51, 2792-9	7.5	202
225	Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. <i>Cancer</i> , 2016 , 122, 3344-3353	6.4	199
224	Immune checkpoint inhibitors in challenging populations. <i>Cancer</i> , 2017 , 123, 1904-1911	6.4	194
223	High response rate to PD-1 blockade in desmoplastic melanomas. <i>Nature</i> , 2018 , 553, 347-350	50.4	178
222	Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis. <i>New England Journal of Medicine</i> , 2019 , 380, 2377-2379	59.2	176
221	Cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Cardiovascular Research</i> , 2019 , 115, 854-868	9.9	167
220	The efficacy of anti-PD-1 agents in acral and mucosal melanoma. <i>Cancer</i> , 2016 , 122, 3354-3362	6.4	164
219	Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3697-704	2.2	158
218	Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology. <i>Circulation</i> , 2019 , 140, 80-91	16.7	153
217	Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. <i>Clinical Cancer Research</i> , 2018 , 24, 5347-5356	12.9	140
216	Immune Checkpoint Inhibitor Toxicity in 2018. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 1702-1703	27.4	139
215	Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2018 , 36, 667-673	2.2	138
214	Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study 2019 , 7, 134		137
213	Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 435-446	12.7	128
212	Biological Consequences of MHC-II Expression by Tumor Cells in Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 2392-2402	12.9	114
211	Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. <i>Cancer Immunology Research</i> , 2015 , 3, 288-295	12.5	111
210	Nivolumab in melanoma: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2015 , 7, 97-106	5.4	108

209	Smoldering myocarditis following immune checkpoint blockade 2017 , 5, 91		100
208	Cardiovascular Toxicities Associated with Cancer Immunotherapies. <i>Current Cardiology Reports</i> , 2017 , 19, 21	4.2	99
207	Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. <i>Immunotherapy</i> , 2015 , 7, 611-9	3.8	98
206	Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. <i>OncImmunology</i> , 2017 , 6, e1344805	7.2	97
205	Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma. <i>Oncologist</i> , 2017 , 22, 963-971	5.7	96
204	Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution. <i>Circulation</i> , 2018 , 138, 743-745	16.7	91
203	Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation. <i>Cancer Discovery</i> , 2017 , 7, 1248-1265	24.4	90
202	Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy 2017 , 5, 8		86
201	Treatment of NRAS-mutant melanoma. <i>Current Treatment Options in Oncology</i> , 2015 , 16, 15	5.4	86
200	Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. <i>Cancer Immunology Research</i> , 2013 , 1, 373-7	12.5	86
199	Cardiovascular Toxicities Associated With Ibrutinib. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1667-1678	15.1	85
198	Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015 , 33, e122-4	2.2	82
197	A case report of clonal EBV-like memory CD4 T cell activation in fatal checkpoint inhibitor-induced encephalitis. <i>Nature Medicine</i> , 2019 , 25, 1243-1250	50.5	80
196	Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. <i>Oncologist</i> , 2014 , 19, 616-22	5.7	80
195	Integrated genomic analyses reveal frequent aberrations in acral melanoma. <i>Genome Research</i> , 2017 , 27, 524-532	9.7	78
194	Conserved Interferon- β Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. <i>Cancer Cell</i> , 2020 , 38, 500-515.e3	24.3	75
193	Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. <i>Cancer Immunology Research</i> , 2015 , 3, 464-9	12.5	71
192	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>Journal of Clinical Oncology</i> , 2020 , 38, 576-583	2.2	71

191	A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 1918-28	6.1	69
190	Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. <i>JCI Insight</i> , 2018 , 3,	9.9	68
189	A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy. <i>Journal of Clinical Investigation</i> , 2020 , 130, 2570-2586	15.9	66
188	NCCN Guidelines Insights: Melanoma, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 945-58	7.3	66
187	Combinatorial approach to cancer immunotherapy: strength in numbers. <i>Journal of Leukocyte Biology</i> , 2016 , 100, 275-90	6.5	65
186	Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2018 , 24, 5250-5260	12.9	65
185	Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition. <i>Journal of Immunotherapy</i> , 2017 , 40, 31-35	5	62
184	Melanoma: What do all the mutations mean?. <i>Cancer</i> , 2018 , 124, 3490-3499	6.4	62
183	Hematologic Complications of Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2019 , 24, 584-588	5.7	61
182	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events 2021 , 9,		58
181	Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma. <i>JAMA Oncology</i> , 2019 , 5, 906-908	13.4	56
180	Immune checkpoint inhibitors in NSCLC. <i>Current Treatment Options in Oncology</i> , 2014 , 15, 658-69	5.4	56
179	Therapeutic Advances and Treatment Options in Metastatic Melanoma. <i>JAMA Oncology</i> , 2015 , 1, 380-6	13.4	55
178	Beyond histology: translating tumor genotypes into clinically effective targeted therapies. <i>Clinical Cancer Research</i> , 2014 , 20, 2264-75	12.9	51
177	Toxicities Associated With PD-1/PD-L1 Blockade. <i>Cancer Journal (Sudbury, Mass)</i> , 2018 , 24, 36-40	2.2	49
176	Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia. <i>Clinical Cancer Research</i> , 2014 , 20, 4186-92	12.9	49
175	A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. <i>Cancer Discovery</i> , 2021 , 11, 614-625	24.4	49
174	Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes. <i>Diabetes Care</i> , 2018 , 41, e150-e151	14.1	49

173	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. <i>JAMA Oncology</i> , 2021 ,	13.4	47
172	Mass cytometry deep phenotyping of human mononuclear phagocytes and myeloid-derived suppressor cells from human blood and bone marrow. <i>Journal of Leukocyte Biology</i> , 2017 , 102, 437-447	6.5	46
171	Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction 2016 , 4, 60		46
170	Targeted Therapy in Advanced Melanoma With Rare Mutations. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3142-3151	2.2	43
169	MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	43
168	Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling. <i>Oncotmunology</i> , 2017 , 6, e1305535	7.2	40
167	Update on the targeted therapy of melanoma. <i>Current Treatment Options in Oncology</i> , 2013 , 14, 280-92	5.4	40
166	Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma 2017 , 5, 1		37
165	Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, -glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma. <i>Molecular and Cellular Proteomics</i> , 2017 , 16, 1705-1717	7.6	36
164	COVID-19 and immune checkpoint inhibitors: initial considerations 2020 , 8,		36
163	Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. <i>Lancet Oncology, The</i> , 2020 , 21, e398-e404	21.7	35
162	Immune-checkpoint inhibitors: long-term implications of toxicity.. <i>Nature Reviews Clinical Oncology</i> , 2022 ,	19.4	34
161	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. <i>Lancet Oncology, The</i> , 2021 , 22, 836-847	21.7	33
160	Neurologic complications of immune checkpoint inhibitors. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 479-488		32
159	Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?. <i>American Journal of Transplantation</i> , 2020 , 20, 879-883	8.7	32
158	Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K -Mutant Melanoma. <i>Clinical Cancer Research</i> , 2019 , 25, 1272-1279	12.9	32
157	Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 114-117	7.3	31
156	Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis. <i>Oncologist</i> , 2020 , 25, 696-701	5.7	31

155	Emerging biomarkers for cancer immunotherapy in melanoma. <i>Seminars in Cancer Biology</i> , 2018 , 52, 207-215	21.5	31
154	Endocrine toxicities of immune checkpoint inhibitors. <i>Nature Reviews Endocrinology</i> , 2021 , 17, 389-399	15.2	30
153	Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy. <i>Cancer</i> , 2019 , 125, 884-891	6.4	30
152	Systems immune monitoring in cancer therapy. <i>European Journal of Cancer</i> , 2016 , 61, 77-84	7.5	29
151	Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. <i>American Journal of Hematology</i> , 2019 , 94, 563-574	7.1	29
150	A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. <i>Cancer</i> , 2019 , 125, 1113-1123	6.4	28
149	Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review. <i>Oncologist</i> , 2015 , 20, 648-52	5.7	28
148	Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. <i>Autoimmunity Reviews</i> , 2020 , 19, 102586	13.6	28
147	Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study 2020 , 8,		28
146	Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. <i>JCO Precision Oncology</i> , 2017 , 2017,	3.6	28
145	Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. <i>Oncolimmunology</i> , 2018 , 7, e1438106	7.2	27
144	Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. <i>JAMA Oncology</i> , 2021 , 7, 744-748	13.4	25
143	Clinical characterization of colitis arising from anti-PD-1 based therapy. <i>Oncolimmunology</i> , 2019 , 8, e1524695	6.95	25
142	Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma. <i>Cancer Immunology Research</i> , 2017 , 5, 357-362	12.5	24
141	PD-1/PD-L1 blockade in renal cell cancer. <i>Expert Review of Clinical Immunology</i> , 2017 , 13, 77-84	5.1	24
140	Impact of body composition on outcomes from anti-PD1 +/- anti-CTLA-4 treatment in melanoma 2020 , 8,		23
139	Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 4583-4591	11.5	21
138	Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?. <i>Clinical Cancer Research</i> , 2019 , 25, 1452-1454	12.9	21

137	Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. <i>Pigment Cell and Melanoma Research</i> , 2019 , 32, 553-563	4.5	20
136	Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 Therapy. <i>Cancer Immunology Research</i> , 2020 , 8, 851-855	12.5	20
135	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors 2021 , 9,		20
134	Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy. <i>Oncologist</i> , 2019 , 24, 872-876	3.6	20
133	Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand. <i>European Journal of Cancer</i> , 2020 , 135, 211-220	7.5	19
132	BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy. <i>Pigment Cell and Melanoma Research</i> , 2018 , 31, 432-436	4.5	19
131	Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma. <i>Current Oncology Reports</i> , 2016 , 18, 6	6.3	19
130	Responses to immune checkpoint inhibitors in nonagenarians. <i>Oncolmmunology</i> , 2016 , 5, e1234572	7.2	19
129	Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 1778-1789	3.8	18
128	Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab. <i>Cancer Immunology Research</i> , 2016 , 4, 569-73	12.5	18
127	Management of V600E and V600K BRAF-Mutant Melanoma. <i>Current Treatment Options in Oncology</i> , 2019 , 20, 81	5.4	18
126	Class Matters: Sensitivity of -Mutant Melanoma to MAPK Inhibition. <i>Clinical Cancer Research</i> , 2018 , 24, 6107-6109	12.9	17
125	The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma. <i>JCI Insight</i> , 2018 , 3,	9.9	17
124	The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma. <i>Oncologist</i> , 2020 , 25, e602-e605	5.7	17
123	Emerging targeted therapies for melanoma. <i>Expert Opinion on Emerging Drugs</i> , 2016 , 21, 195-207	3.7	17
122	Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131). <i>Clinical Cancer Research</i> , 2020 , 26, 1812-1819	12.9	17
121	Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma. <i>Clinical Cancer Research</i> , 2021 , 27, 131-140	12.9	17
120	Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance. <i>Annual Review of Pharmacology and Toxicology</i> , 2021 , 61, 85-112	17.9	17

119	Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis. <i>European Journal of Cancer</i> , 2019 , 113, 10-13	7.5	16
118	Correlates of response and outcomes with talimogene laherperpvec. <i>Journal of Surgical Oncology</i> , 2019 , 120, 558-564	2.8	16
117	Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types. <i>Cancer Immunology Research</i> , 2019 , 7, 86-99	12.5	16
116	Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis 2020 , 8,		15
115	Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum. <i>Pigment Cell and Melanoma Research</i> , 2016 , 29, 470-3	4.5	15
114	Balancing Cancer Immunotherapy Efficacy and Toxicity. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020 , 8, 2898-2906	5.4	14
113	Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy. <i>Cancer Immunology Research</i> , 2016 , 4, 474-480	12.5	14
112	Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach. <i>Oncotarget</i> , 2015 , 6, 2496-508	3.3	14
111	Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome. <i>Science Advances</i> , 2020 , 6,	14.3	14
110	Immune Checkpoint Inhibitor Therapy in Patients With Autoimmune Disease. <i>Oncology</i> , 2018 , 32, 190-4	1.8	14
109	Trametinib in the treatment of melanoma. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15, 735-47	5.4	12
108	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <i>Cancer Cell</i> , 2020 , 38, 761-766	24.3	12
107	Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management 2020 , 8,		12
106	Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. <i>Clinical Cancer Research</i> , 2020 , 26, 3803-3818	12.9	12
105	Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. <i>JCO Precision Oncology</i> , 2017 , 1,	3.6	11
104	Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study. <i>JAMA Oncology</i> , 2021 ,	13.4	11
103	Hematological immune related adverse events after treatment with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021 , 147, 170-181	7.5	11
102	Anti-PD-1-Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients. <i>Cancer Immunology Research</i> , 2019 , 7, 1755-1759	12.5	11

101	Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2019 , 42, 221-227	5	11
100	The State of Melanoma: Emergent Challenges and Opportunities. <i>Clinical Cancer Research</i> , 2021 , 27, 2678-2697	12.9	11
99	Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy. <i>Clinical Cancer Research</i> , 2021 , 27, 5993-6000	12.9	11
98	Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R. <i>Oncogenesis</i> , 2020 , 9, 44	6.6	10
97	Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma. <i>Cancer Discovery</i> , 2021 , 11, 1996-2013	24.4	10
96	Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review. <i>European Journal of Cancer</i> , 2021 , 148, 36-47	7.5	10
95	Rationale for Harnessing the Abscopal Effect as Potential Treatment for Metastatic Uveal Melanoma. <i>International Ophthalmology Clinics</i> , 2017 , 57, 41-48	1.7	9
94	The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma. <i>Frontiers in Oncology</i> , 2018 , 8, 584	5.3	9
93	Immunotherapy in Older Adults with Cancer. <i>Current Oncology Reports</i> , 2019 , 21, 56	6.3	9
92	Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond. <i>American Journal of Clinical Dermatology</i> , 2018 , 19, 181-193	7.1	9
91	Continued Poor Survival in Metastatic Uveal Melanoma: Implications for Molecular Prognostication, Surveillance Imaging, Adjuvant Therapy, and Clinical Trials. <i>JAMA Ophthalmology</i> , 2018 , 136, 986-988	3.9	9
90	Immunotherapy for Uveal Melanoma. <i>International Ophthalmology Clinics</i> , 2017 , 57, 29-39	1.7	9
89	429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma 2020 , 8, A454-A454		9
88	Cancer immunotherapy-related adverse events: causes and challenges. <i>Supportive Care in Cancer</i> , 2020 , 28, 6111-6117	3.9	9
87	Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. <i>Circulation Research</i> , 2021 , 128, 1780-1801	15.7	9
86	Cutaneous adverse events caused by immune checkpoint inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 956-966	4.5	9
85	Melanoma driver mutations and immune therapy. <i>Oncolmmunology</i> , 2016 , 5, e1051299	7.2	8
84	Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. <i>JAMA Network Open</i> , 2021 , 4, e2134330	10.4	8

83	ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. <i>Oncotarget</i> , 2015 , 6, 22348-60	3.3	8
82	Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors. <i>Cancer</i> , 2020 , 126, 322-328	6.4	8
81	A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2016 , 29, 101-3	4.5	8
80	COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021 , 155, 291-293	7.5	8
79	A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. <i>Oncolimmunology</i> , 2021 , 10, 1875639	7.2	8
78	Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations. <i>Molecular Cancer Research</i> , 2019 , 17, 1842-1853	6.6	7
77	Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. <i>Journal of Leukocyte Biology</i> , 2020 , 108, 1455-1489	6.5	7
76	Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019 , 123, 112-115	7.5	7
75	The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer. <i>BioDrugs</i> , 2020 , 34, 495-503	7.9	7
74	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities. <i>Supportive Care in Cancer</i> , 2020 , 28, 6175-6181	3.9	7
73	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020 , 28, 6129-6143	3.9	7
72	Defining and Targeting BRAF Mutations in Solid Tumors. <i>Current Treatment Options in Oncology</i> , 2021 , 22, 30	5.4	7
71	Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data 2021 , 9,		7
70	Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma. <i>Cancer</i> , 2020 , 126, 3448-3455	6.4	6
69	MDM2 Antagonists Counteract Drug-Induced DNA Damage. <i>EBioMedicine</i> , 2017 , 24, 43-55	8.8	6
68	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020 , 28, 6119-6128	3.9	6
67	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. <i>Supportive Care in Cancer</i> , 2020 , 28, 6145-6157	3.9	6
66	Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	5

65	Predictive biomarkers of response to immune checkpoint inhibitors in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 137-145	3.5	5
64	Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. <i>European Journal of Cancer</i> , 2021 , 148, 61-75	7.5	5
63	Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade. <i>Molecular Cancer</i> , 2021 , 20, 85	42.1	5
62	Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2. <i>Journal of Investigative Medicine</i> , 2021 ,	2.9	5
61	Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer. <i>Cancer Discovery</i> , 2021 ,	24.4	5
60	Melanoma and a Headache. Diagnosis: Hypophysitis. <i>JAMA Oncology</i> , 2015 , 1, 1167-8	13.4	4
59	Reporting of immune checkpoint inhibitor-associated myocarditis - AuthorsPreply. <i>Lancet, The</i> , 2018 , 392, 384-385	4.0	4
58	MEK inhibitors in non-V600 BRAF mutations and fusions. <i>Oncotarget</i> , 2020 , 11, 3900-3903	3.3	4
57	Adjuvant pembrolizumab versus interferon alfa-2b or ipilimumab in resected high-risk melanoma. <i>Cancer Discovery</i> , 2021 ,	24.4	4
56	Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy 2021 , 9,		4
55	Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders 2021 , 9,		4
54	Advances in the development of intralesional therapies for melanoma. <i>Melanoma Management</i> , 2016 , 3, 259-266	2.1	4
53	Pragmatic precision oncology: the secondary uses of clinical tumor molecular profiling. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016 , 23, 773-6	8.6	4
52	Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer. <i>Medical Mycology Case Reports</i> , 2014 , 6, 34-6	1.7	3
51	Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2021 , 12, 786046	8.4	3
50	Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer. <i>Frontiers in Pharmacology</i> , 2021 , 12, 743582	5.6	3
49	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020 , 28, 6159-6173	3.9	3
48	Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study. <i>Oncologist</i> , 2021 , 26, 731-e1498	5.7	3

47	Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2021 , 153, 213-222	7.5	3
46	Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. 2022 , 10,		2
45	Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101701	2.2	2
44	Biomarkers for immune therapy in melanoma. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2018 , 37, 120-126	1.4	2
43	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.. <i>European Journal of Cancer</i> , 2021 , 162, 22-33	7.5	2
42	Supportive care for new cancer therapies. <i>Current Opinion in Oncology</i> , 2021 , 33, 287-294	4.2	2
41	Treatment of infections in cancer patients: an update from the neutropenia, infection and myelosuppression study group of the Multinational Association for Supportive Care in Cancer (MASCC). <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 295-313	3.8	2
40	Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 1623-1634	5.4	2
39	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. <i>European Journal of Cancer</i> , 2021 , 151, 72-83	7.5	2
38	Advanced Melanoma: Resistance Mechanisms to Current Therapies. <i>Hematology/Oncology Clinics of North America</i> , 2021 , 35, 111-128	3.1	2
37	Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. <i>European Journal of Cancer</i> , 2021 , 153, 168-178	7.5	2
36	Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Institute-Designated Comprehensive Cancer Center. <i>Oncologist</i> , 2021 , 26, e1962-e1970	5.7	2
35	High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy. <i>Clinical Hematology International</i> , 2021 , 3, 96-102	1.8	2
34	Adverse Events Associated With Immune Checkpoint Inhibitors-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 1219-1220	27.4	1
33	BRAFV600E-mutant melanoma presenting with cardiac involvement. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 611-5	7.3	1
32	Clinical Response to Anti-Programmed Death 1 After Response and Subsequent Progression on Anti-Programmed Death Ligand 1 Therapy. <i>JCO Precision Oncology</i> , 2017 , 1,	3.6	1
31	Biomarkers in melanoma: where are we now?. <i>Melanoma Management</i> , 2014 , 1, 139-150	2.1	1
30	Adult neuroblastoma complicated by increased intracranial pressure: a case report and review of the literature. <i>Case Reports in Oncological Medicine</i> , 2014 , 2014, 341980	0.9	1

29	Proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patients.. <i>Npj Precision Oncology</i> , 2022 , 6, 6	9.8	1
28	The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma.. <i>BMC Cancer</i> , 2022 , 22, 38	4.8	1
27	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter Analysis. <i>Frontiers in Oncology</i> , 2021 , 11, 765608	5.3	1
26	A Multicenter Analysis of Immune Checkpoint Inhibitors as Adjuvant Therapy Following Treatment of Isolated Brain Metastasis. <i>Oncologist</i> , 2021 , 26, e505-e507	5.7	1
25	Prognostic Clinical and Radiographic Biomarkers for BRAF-Targeted Therapy in Advanced Melanoma. <i>Oncologist</i> , 2021 , 26, e333-e335	5.7	1
24	Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Events-Reply. <i>JAMA Oncology</i> , 2021 , 7, 1574-1575	13.4	1
23	Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates 2019 , 7, 123		0
22	Follow-up recommendations for chest CT scan reports of incidental pulmonary nodules. <i>Chest</i> , 2012 , 141, 280-281	5.3	0
21	Novel insights into the pathogenesis and treatment of NRAS mutant melanoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021 , 6, 281-294	1.6	0
20	Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - AuthorsPreply. <i>Lancet Oncology, The</i> , 2021 , 22, e343-e344	21.7	0
19	Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and Models.. <i>Immunology and Allergy Clinics of North America</i> , 2022 , 42, 285-305	3.3	0
18	Enabling a genetically informed approach to cancer medicine: evaluation of the impact of comprehensive tumor sequencing. <i>Personalized Medicine</i> , 2017 , 14, 189-192	2.2	
17	Longer Survival With Anti-Programmed Cell Death 1 and Development of Cutaneous Toxic Effects, an Expected Association-In Reply. <i>JAMA Oncology</i> , 2019 , 5, 1642-1643	13.4	
16	Targeting tissue factor in advanced solid tumours. <i>Lancet Oncology, The</i> , 2019 , 20, 318-319	21.7	
15	Treatment of elderly patients with melanoma. <i>Memo - Magazine of European Medical Oncology</i> , 2016 , 9, 13-16	0.3	
14	Targeted Therapy in Advanced Melanoma 2019 , 667-686		
13	The MEK inhibitor trametinib for the treatment of advanced melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 1341-1349	1.1	
12	Targeted Therapies for BRAF-Mutant Metastatic Melanoma 2020 , 1067-1085		

- 11 239 Efficacy and toxicity of single agent immune checkpoint inhibitors among adults with cancer aged **80** years: a multicenter international cohort study **2021**, 9, A257-A257
- 10 812 Erythema nodosum-like toxicity in an immunotherapy treated patient is accompanied by oligoclonal memory activated CD4 T cells **2021**, 9, A848-A848
- 9 The role of plastic surgery in the immune checkpoint inhibitor era. *Journal of Plastic, Reconstructive and Aesthetic Surgery*, **2021**, 1.7
- 8 Targeted Therapies for BRAF-Mutant Metastatic Melanoma **2019**, 1-19
- 7 Clinical Utility of BRAF-Targeted Therapy in Melanoma. *Cancer Drug Discovery and Development*, **2015**, 67-84 0.3
- 6 Update on immune therapy in melanoma. *Expert Opinion on Orphan Drugs*, **2016**, 4, 799-808 1.1
- 5 Empiric Therapy with BRAF and MEK Inhibitors in Metastatic Melanoma. *Oncologist*, **2019**, 24, 1495-1496 5.7
- 4 Surveillance for Metastatic Disease **2021**, 153-171
- 3 Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety. *Expert Review of Anticancer Therapy*, **2021**, 21, 583-590 3.5
- 2 Targeted Therapy in Advanced Melanoma **2018**, 1-20
- 1 Primed for toxicity: CD4+ T cells and immune checkpoint inhibitors.. *Med*, **2022**, 3, 155-156 31.7